Page last updated: 2024-12-07

3',5'-diiodothyronine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3',5'-diiodothyronine: RN given refers to (DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50986088
CHEBI ID195762
MeSH IDM0095514

Synonyms (4)

Synonym
3',5'-diiodothyronine
(2s)-2-azaniumyl-3-[4-(4-hydroxy-3,5-diiodophenoxy)phenyl]propanoate
CHEBI:195762
3',5'-diiodo-l-thyronine

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
thyroid hormone metabolism I (via deiodination)414

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (64.10)18.7374
1990's7 (17.95)18.2507
2000's4 (10.26)29.6817
2010's1 (2.56)24.3611
2020's2 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (9.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (90.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]